City

Iowa City (1)

London (1)

Seattle (1)

Tianjin (1)

Overall Status

Recruiting (2)

Completed (1)

Withdrawn (1)

Phase

early phase 1 (1)

phase 2 (1)

phase 4 (1)

Sponsor

Bloodworks (1)

Charles M Knudson (1)

Imperial College Healthcare NHS Trust (1)

Tianjin Medical University Cancer Institute and Hospital (1)

Collaborator

Imperial College London (1)

Oxford University Hospitals NHS Trust (1)

University of Oxford (1)

University of Washington (1)

Intervention

bms-986413 (1)

bms-986414 (1)

brain radiation therapy (1)

n-acetylcysteine (1)

pyrrotini (1)

Study Documents

Intervention Type

drug (2)

biological (1)

radiation (1)

Funder Type

Other (4)

Study Type

Interventional (3)

Observational [Patient Registry] (1)

ttp

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Antibody-mediated Rejection, NMO Spectrum Disorder, TTP Trial in Iowa City

Recruiting

Antibody-mediated Rejection
+3 more

Iowa City, Iowa

DeGowin blood Center

Oct 31, 2022

SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease, Myeloma Trial in London (BMS-986414, BMS-986413)

Withdrawn

SARS-CoV2 Infection
+6 more

BMS-986414
BMS-986413

London, United Kingdom

Imperial College Heathcare NHS Trust

May 24, 2022

TTP Trial in Tianjin (PYRROTINI, Brain radiation therapy)

Recruiting

PYRROTINI
Brain radiation therapy

Tianjin, China

Tianjin Medical University Cancer Institute and Hospital

Feb 22, 2021

Purpura, Thrombotic Thrombocytopenic, TTP Trial in Seattle (N-Acetylcysteine)

Completed

Purpura, Thrombotic Thrombocytopenic
TTP

N-Acetylcysteine

Seattle, Washington

Puget Sound Blood Center

Sep 18, 2017